ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0498

ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease

Jacob Welch1, Yangyuna Yang1, Joshua Baker2, Katherine Wysham3, Dana Ascherman4, Paul Monach5, Gail Kerr6, Andreas Reimold7, grant Cannon8, Gary Kunkel9, William Robinson10, Michael Duryee1, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5VA Boston Healthcare System, Boston, MA, 6Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 7Dallas VA Medical Center, Dallas, TX, 8University of Utah and Salt Lake City VA, Salt Lake City, UT, 9University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 10Stanford University, Palo Alto, CA

Meeting: ACR Convergence 2024

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), interstitial lung disease, rheumatoid arthritis, Rheumatoid Factor, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for approximately 6% of all RA deaths. While anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are associated with prevalent RA-ILD, their role in predisposing to RA-ILD onset is not well established, particularly for ACPA subtypes and RF isotypes. The purpose of this study was to investigate ACPA subtypes and RF isotypes as predictors of prevalent and incident RA-ILD.

Methods: Within a large, multicenter prospective cohort of U.S. Veterans with RA, we performed a cross-sectional study of prevalent RA-ILD and a cohort study of incident RA-ILD. RA-ILD diagnoses were systematically captured with an informatics-based screening approach and validated by a board-certified rheumatologist through standardized medical record review of clinical diagnoses, chest imaging, and pathology. Individuals with prevalent RA-ILD (diagnosed before enrollment) were excluded from incident analyses. Concentrations of RF isotypes (IgA, IgM, IgG) and ACPA subtypes (n=18 ACPAs) were measured via ELISA or a multiplex bead-based assay, respectively, using serum from enrollment then log-transformed and standardized. Multivariable logistic (prevalent RA-ILD) and Cox (incident RA-ILD) regression models were used to evaluate the individual associations of RF/ACPAs with RA-ILD adjusting for age, sex, race, and smoking status. Additional models adjusted for commercial anti-CCP antibody positivity to evaluate additive prediction.

Results: Among 1666 participants with RF isotypes (mean age 63.5 years, 90.7% male), 66 had prevalent RA-ILD while 122 developed incident RA-ILD. Characteristics were similar among participants with ACPA subtypes where 58 of 1,458 participants had prevalent RA-ILD, and 108 developed incident RA-ILD. Higher concentrations of IgA (aOR per 1 SD 1.84, 1.33-2.56), IgM (aOR 1.81, 1.30-2.53), and IgG (aOR 1.60, 1.22-2.10) RF were associated with prevalent RA-ILD (Table 1).  Six of eighteen ACPA subtypes were significantly associated with prevalent RA-ILD, with three remaining associated independent of commercial anti-CCP positivity (vimentin cit, h2b cit, h2a cit). Higher concentrations of IgA (aHR 1.41, 1.15-1.74), IgM (aHR 1.41, 1.14-1.74) and IgG (aHR 1.34, 1.11-1.61) RF were also significantly associated with incident RA-ILD (Table 2). Among ACPAs, only anti-cit-fibrinogen was associated with incident RA-ILD, which did not persist after adjustment for commercial anti-CCP positivity. RA patients with the highest values of IgA, IgM, and IgG RF isotypes had a 1.4 to >2-fold higher risk of developing incident ILD (tertile 3 vs. tertile 1, Figure 1).

Conclusion: RF isotypes, particularly IgA and IgM, are more closely associated with prevalent and incident RA-ILD in RA than ACPA subtypes. RF antibodies may precede clinical disease, and measurement of RF isotypes may aid in risk stratification for incident RA-ILD.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Welch: None; Y. Yang: None; J. Baker: Cumberland Pharma, 2, Formation Bio, 2, Horizon, 5; K. Wysham: None; D. Ascherman: None; P. Monach: HI-Bio, 2; G. Kerr: AstraZeneca, 1, Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 1, CSL Behring, 6, Janssen, 6, Novartis, 1, Pfizer, 6, Sanofi, 6, UCB, 1; A. Reimold: None; g. Cannon: None; G. Kunkel: None; W. Robinson: Janssen, 5; M. Duryee: None; G. Thiele: None; T. Mikuls: Elsevier, 9, Horizon Therapeutics, 2, 5, Pfizer, 2, Sanofi, 2, UCB Pharma, 2, Wolters Kluwer Health (UpToDate), 9; B. England: Boehringer-Ingelheim, 5.

To cite this abstract in AMA style:

Welch J, Yang Y, Baker J, Wysham K, Ascherman D, Monach P, Kerr G, Reimold A, Cannon g, Kunkel G, Robinson W, Duryee M, Thiele G, Mikuls T, England B. ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/acpa-subtypes-rf-isotypes-and-the-risk-of-rheumatoid-arthritis-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acpa-subtypes-rf-isotypes-and-the-risk-of-rheumatoid-arthritis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology